Clinical Trial Update: Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513 [EARLY_Phase 1]

View source ↗

Summary

An EARLY_PHASE1 clinical trial evaluating the safety and efficacy of the PET imaging agent MNI-513 for Alzheimer's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• MNI-513

Snippet

Sponsor: Institute for Neurodegenerative Disorders | Conditions: Alzheimer Disease | EARLY_Phase 1 | Status: TERMINATED